Clinical Trial News and Research

RSS

Victhom second-quarter revenues decrease 94.4% to $27,901

Victhom Human Bionics Inc. today reported its second quarter 2010 financial results.

27 Aug 2010

Recent releases in Global Health

"[N]ew diagnostic techniques [for tuberculosis] need to be studied in children," according to a Lancet Infectious Diseases Reflection. "Tuberculosis is an important cause of morbidity and mortality in children worldwide, but estimates of disease burden are inaccurate because most cases are not confirmed," the author writes. He discusses a study published in the same issue that examines various methods for diagnosing TB in children.

27 Aug 2010

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

Transcatheter heart valve replacement recipient celebrates 102nd birthday

When Doris Snyder celebrated her 102nd birthday on August 10, she was that much closer to the expected birth of her first great-granddaughter who's due to arrive early September. She is very excited about the milestone, which might not have been possible were it not for a cutting-edge, experimental procedure that replaced one of Doris' heart valves weeks earlier when she was 101. The valve had been rendered useless by aortic valve stenosis—hardening from calcium deposits that restrict the flow of blood from the heart.

27 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.

27 Aug 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Neuroscientists in the Down Syndrome Research Group at the University of Arizona have created a battery of tests that quickly aid in the assessment of the cognitive abilities of persons with Down syndrome.

27 Aug 2010

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Vanda Pharmaceuticals Inc., today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.

26 Aug 2010

Seven year Aspirin for cancer trial

A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.

26 Aug 2010

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

26 Aug 2010

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for various forms of cancer and other diseases, today announced its second quarter 2010 financial results.

26 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

Octapharma completes clinical development of Uniplas human pooled plasma

Octapharma AG, one of the largest private manufacturers of plasma products in the world, announced today that the clinical development for Uniplas® has been successfully completed. The product has been filed for registration in Europe and will be submitted later in the USA.

26 Aug 2010

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial.

26 Aug 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

Lockheed Martin awarded contracts to accelerate advancement of Nationwide Health Information Network

Lockheed Martin will take steps to accelerate the advancement of digital health records and secure health information exchanges with two new agreements to support the Nationwide Health Information Network. The contracts, which were awarded by the Department of Health and Human Services' Office of the National Coordinator for Health Information Technology (ONC), total $9 million over two years.

26 Aug 2010

Clinical Trial News and Research

Victhom second-quarter revenues decrease 94.4% to $27,901

Recent releases in Global Health

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Transcatheter heart valve replacement recipient celebrates 102nd birthday

FDA approves Novartis' Tekamlo for treatment of high blood pressure

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Vanda Pharmaceuticals initiates tasimelteon Phase III clinical trial for Non-24-Hour Sleep Wake Disorder

Seven year Aspirin for cancer trial

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

NeoPharm second-quarter net loss decreases to $0.8 million

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Octapharma completes clinical development of Uniplas human pooled plasma

Researchers show biosynthetic cornea can stimulate regeneration in damaged eye tissue

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Treating metastatic melanoma tumors with specific genetic signature shows promising results

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Lockheed Martin awarded contracts to accelerate advancement of Nationwide Health Information Network

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News